Patents Assigned to HANSA BIOPHARMA AB
-
Patent number: 12359183Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.Type: GrantFiled: May 16, 2023Date of Patent: July 15, 2025Assignee: Hansa Biopharma ABInventors: Christian Kjellman, Sofia Jarnum, Emma Andersson Nordahl
-
Publication number: 20230210962Abstract: The present invention relates to a conditioning regimen for the transplant of a cell, tissue or organ, optionally hematopoietic stem / progenitor cells, to a subject. The invention also relates to methods for the induction of hematopoietic chimerism in a subject. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject, in which hematopoietic chimerism is induced in order to improve the benefit to the subject of a subsequent therapy. The subsequent therapy may be a cell, tissue or organ transplant or may a gene therapy administered using genetically modified hematopoietic stem cells/progenitor cells.Type: ApplicationFiled: March 3, 2021Publication date: July 6, 2023Applicant: Hansa Biopharma ABInventors: Robert Bockermann, Anna-Karin Louise Robertson, Jiaxin LIN, Colin Charles ANDERSON
-
Publication number: 20230181701Abstract: The present invention relates to methods for enhancing adoptive cell transfer immunotherapy by administering a protein that has IgG cysteine protease or IgG endoglycosidase activity.Type: ApplicationFiled: May 18, 2021Publication date: June 15, 2023Applicant: Hansa Biopharma ABInventor: Christian Kjellman
-
Patent number: 11667905Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.Type: GrantFiled: December 14, 2021Date of Patent: June 6, 2023Assignee: HANSA BIOPHARMA ABInventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
-
Publication number: 20230110085Abstract: The present invention relates to improved methods for detecting immunoglobulin M (IgM), immunoglobulin A (IgA) and immunoglobulin E (IgE) antibodies, and new therapies for diseases and conditions mediated by pathogenic antibodies and antibody complexes.Type: ApplicationFiled: February 12, 2021Publication date: April 13, 2023Applicant: Hansa Biopharma ABInventors: Anna RUNSTRÖM, Robert BOCKERMANN, Kristoffe SJÖHOLM, Markus ROUPÉ, Christian KJELLMAN, Tomas LORANT
-
Patent number: 11214784Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.Type: GrantFiled: May 20, 2020Date of Patent: January 4, 2022Assignee: Hansa BioPharma ABInventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
-
Patent number: 10758597Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.Type: GrantFiled: February 12, 2016Date of Patent: September 1, 2020Assignee: HANSA BIOPHARMA ABInventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
-
Patent number: 10696959Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.Type: GrantFiled: February 12, 2016Date of Patent: June 30, 2020Assignee: HANSA BIOPHARMA ABInventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl